The IFI27 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the IFI27 gene has been disrupted using CRISPR/Cas9-mediated gene editing. This product provides a heterogeneous pool of A-549 cells carrying diverse loss-of-function mutations in IFI27, enabling robust functional studies without clonal artifacts. The polyclonal format preserves population-level complexity while eliminating IFI27 protein expression, making it suitable for high-throughput screening, pooled genetic analysis, and pathway interrogation. By targeting the IFI27 locus, researchers can investigate the gene??s role in apoptosis regulation, interferon signaling, and mitochondrial function in a physiologically relevant lung adenocarcinoma background.
The parental A-549 cell line is a well-established human lung adenocarcinoma epithelial cell line originally derived from the explanted lung tissue of a 58-year-old Caucasian male. A-549 cells retain alveolar epithelial characteristics and are widely employed as a model for studying non-small cell lung cancer (NSCLC) biology, including oncogenic signaling, drug metabolism, and respiratory pathogen interactions. Their epithelial origin and adherent growth properties facilitate reproducible culture and experimental manipulation. The integration of IFI27 knockout into this background provides a powerful tool for dissecting the interplay between interferon-inducible genes and cancer cell phenotypes in a clinically relevant cell system.
IFI27 encodes interferon alpha-inducible protein 27, a mitochondrial protein transcriptionally regulated by type I interferons via the JAK-STAT pathway. Upon interferon stimulation, receptor engagement at IFNAR1/IFNAR2 complexes activates JAK1 and TYK2 kinases, leading to STAT1 phosphorylation and nuclear translocation, which induces IFI27 expression downstream of IRF1. At the mitochondria, IFI27 interacts with Bcl-2 family members, including Bcl-2, Mcl-1, Bax, and Bak, to modulate mitochondrial outer membrane permeabilization and cytochrome c release. Overexpression of IFI27 inhibits apoptosis, whereas CRISPR/Cas9-mediated disruption sensitizes cells to apoptotic stimuli, indicating its critical role as a pro-survival factor in the intrinsic apoptosis pathway. Additionally, IFI27 influences caspase activation and interferon-driven innate immune responses, linking mitochondrial homeostasis to cellular defense mechanisms.
In A-549 lung adenocarcinoma cells, IFI27 knockout provides a unique platform to study apoptosis resistance mechanisms and interferon signaling crosstalk that contribute to tumor survival and therapeutic response. The A-549 line exhibits wild-type p53 and moderate EGFR expression, making it suitable for investigating how IFI27 loss affects mitochondrial priming and sensitivity to chemotherapy or targeted agents. Given IFI27??s role in viral defense, this knockout model also allows exploration of how interferon-induced mitochondrial proteins influence respiratory virus replication and innate immune evasion. By eliminating IFI27 in an alveolar epithelial context, the model addresses key questions in cancer cell survival, drug sensitivity, and host?Cpathogen dynamics.
Researchers can employ IFI27 Knockout A-549 Polyclonal Cells in a variety of assays, including Western blotting for apoptosis markers such as cleaved caspases and PARP, RT-qPCR to measure interferon-stimulated gene expression, flow cytometry with Annexin V/PI staining to quantify cell death, caspase activity assays, and mitochondrial membrane potential measurements using JC-1 or TMRE dyes. Cell viability assays under treatment with drugs like staurosporine, cisplatin, or interferon-alpha can reveal the functional consequences of IFI27 loss. These cells are also suitable for viral infection models and high-content screening to identify modulators of apoptosis or interferon signaling. For further information and technical support, please contact Ascent Research.
